ESCMID*  	ESCMID*  	 NNP	B-NP
guideline  	guideline  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
diagnosis  	diagnosis  	 NN	O
and  	and  	 CC	O
management  	management  	 NN	O
of  	of  	 IN	O
Candida  	Candida  	 NNP	B-NP
diseases  	diseases  	 VBD	I-NP
2012 	2012 	 CD	O
:  	:  	 :	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
HIV  	HIV  	 NNP	B-NP
infection  	infection  	 NN	I-NP
or  	or  	 CC	O
AIDS  	AIDS  	 NNP	O
Mucosal  	Mucosal  	 NNP	B-NP
candidiasis  	candidiasis  	 NN	I-NP
is  	is  	 VBZ	O
frequent  	frequent  	 JJ	O
in  	in  	 IN	O
immunocompromised  	immunocompromised  	 JJ	B-NP
HIV-infected  	HIV-infected  	 NN	I-NP
highly  	highly  	 RB	O
active  	active  	 JJ	O
antiretroviral  	antiretroviral  	 NNS	B-NP
( 	( 	 -LRB-	O
HAART 	HAART 	 NNP	B-NP
)  	)  	 -RRB-	O
naive  	naive  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
or  	or  	 CC	O
those  	those  	 DT	O
who  	who  	 WP	O
have  	have  	 VBP	O
failed  	failed  	 VBN	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
Mucosal  	Mucosal  	 JJ	B-NP
candidiasis  	candidiasis  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
marker  	marker  	 NN	O
of  	of  	 IN	O
progressive  	progressive  	 JJ	B-NP
immune  	immune  	 JJ	I-NP
deficiency 	deficiency 	 NN	I-NP
.  	.  	 .	O
Because  	Because  	 IN	O
of  	of  	 IN	O
the  	the  	 DT	O
frequently  	frequently  	 RB	O
marked  	marked  	 VBN	O
and  	and  	 CC	O
prompt  	prompt  	 VB	O
immune  	immune  	 JJ	O
reconstitution  	reconstitution  	 JJ	B-NP
induced  	induced  	 NN	I-NP
by  	by  	 IN	O
HAART 	HAART 	 NNP	B-NP
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
no  	no  	 DT	O
recommendation  	recommendation  	 NN	B-NP
for  	for  	 IN	I-NP
primary  	primary  	 JJ	I-NP
antifungal  	antifungal  	 JJ	I-NP
prophylaxis  	prophylaxis  	 NN	I-NP
of  	of  	 IN	I-NP
mucosal  	mucosal  	 JJ	I-NP
candidiasis  	candidiasis  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
HIV  	HIV  	 NNP	B-NP
setting  	setting  	 NN	O
in  	in  	 IN	O
Europe 	Europe 	 NNP	O
,  	,  	 ,	O
although  	although  	 IN	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
evidenced  	evidenced  	 VBN	O
as  	as  	 IN	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
pre-HAART  	pre-HAART  	 JJ	B-NP
era 	era 	 NN	I-NP
.  	.  	 .	O
Fluconazole  	Fluconazole  	 NNP	B-NP
remains  	remains  	 VBZ	O
the  	the  	 DT	O
first  	first  	 JJ	O
line  	line  	 NN	O
of  	of  	 IN	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
both  	both  	 DT	O
oropharyngeal  	oropharyngeal  	 JJ	B-NP
candidiasis  	candidiasis  	 NN	I-NP
and  	and  	 CC	O
oesophageal  	oesophageal  	 JJ	B-NP
candidiasis  	candidiasis  	 NN	I-NP
and  	and  	 CC	O
should  	should  	 MD	O
be  	be  	 VB	O
preferred  	preferred  	 VBN	O
to  	to  	 TO	O
itraconazole  	itraconazole  	 VB	O
oral  	oral  	 JJ	B-NP
solution  	solution  	 NN	I-NP
( 	( 	 -LRB-	O
or  	or  	 CC	O
capsules  	capsules  	 NNS	O
when  	when  	 WRB	O
not  	not  	 RB	O
available 	available 	 JJ	O
)  	)  	 -RRB-	O
due  	due  	 JJ	O
to  	to  	 TO	O
fewer  	fewer  	 JJR	O
side  	side  	 NN	B-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
For  	For  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
still  	still  	 RB	O
present  	present  	 VB	O
with  	with  	 IN	O
fluconazole-refractory  	fluconazole-refractory  	 JJ	B-NP
mucosal  	mucosal  	 JJ	I-NP
candidiasis 	candidiasis 	 NN	I-NP
,  	,  	 ,	O
oral  	oral  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
with  	with  	 IN	O
any  	any  	 DT	O
other  	other  	 JJ	O
azole  	azole  	 NN	B-NP
should  	should  	 MD	O
be  	be  	 VB	O
preferred  	preferred  	 VBN	O
based  	based  	 VBN	O
on  	on  	 IN	O
precise  	precise  	 JJ	O
Candida  	Candida  	 JJ	B-NP
species  	species  	 JJ	I-NP
identification  	identification  	 NN	I-NP
and  	and  	 CC	O
susceptibility  	susceptibility  	 JJ	B-NP
testing  	testing  	 NN	I-NP
results  	results  	 NNS	I-NP
in  	in  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
optimization  	optimization  	 NN	B-NP
of  	of  	 IN	I-NP
HAART  	HAART  	 NNP	I-NP
when  	when  	 WRB	O
feasible 	feasible 	 JJ	O
.  	.  	 .	O
For  	For  	 IN	O
vaginal  	vaginal  	 JJ	B-NP
candidiasis 	candidiasis 	 NN	I-NP
,  	,  	 ,	O
topical  	topical  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
is  	is  	 VBZ	O
preferred 	preferred 	 VBN	O
.  	.  	 .	O
